Instrument Inactif

Communiqués Recipharm publ AB Swiss Exchange

Actions

SE0005757267

Produits pharmaceutiques

Cours en clôture Swiss Exchange
- ^SEK	-

17/02	Scinai Immunotherapeutics Ltd. (NasdaqCM:SCNI) acquiert Recipharm Israel Ltd. auprès de Recipharm AB	CI
20/11	Infant Bacterial Therapeutics AB conclut un partenariat stratégique avec Recipharm Advanced Bio pour la production de sa substance active	CI

Communiqués

03/04/24	Blue Wolf Capital to Acquire OSD CDMO Sites from Recipharm	AQ
27/03/24	Recipharm attains major sustainability milestones	AQ
24/01/24	Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology	AQ
12/12/23	ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas LNP formulations	AQ
06/12/23	Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant	AQ
22/11/23	Marc Funk to transition to Recipharm's Board of Directors, Greg Behar appointed new CEO, Inhaled Business to standalone in 2024	AQ
15/09/23	Fitch Affirm Recipharm at 'B'; Outlook Stable.	AQ
11/09/23	Recipharm - Earthquake in Morocco	AQ
06/09/23	Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy	AQ
18/08/23	Recipharm and Honeywell to speed development of inhalers with a near-zero global warming potential propellant	AQ
12/07/23	Recipharm's new analytical lab brings impressive testing capabilities to global markets	AQ
01/05/23	Arranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeutics	AQ
05/04/23	Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer	AQ
10/03/23	Recipharm's Arranta Bio expands RNA process development capacity by 50 per cent to meet increased customer demand	AQ
24/01/23	PAVM, CHAI & PATH Joint Site Visits With African Vaccine Manufacturers - Fact Finding to Inform Technical and Commercial Support Needed As Well As Near-Term Production Output Forecast	AQ
01/12/22	Recipharm invests in its single dose nasal platform capabilities	AQ
26/10/22	Recipharm bolsters blow-fill-seal capabilities with Lab+	AQ
20/10/22	Recipharm strengthens pre-filled syringe and cartridge offering with new investment	AQ
07/10/22	Biologics Fill/ finish Services Market is projected to be over USD 4.2 billion by 2030 \| Roots Analysis	AQ
30/09/22	Recipharm AB - Transpire Bio announces second agreement with Recipharm for the development of two additional inhaled medicines	AQ
19/07/22	Transpire Bio signs with Recipharm for inhaled medicine development	AQ
15/07/22	Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine	AQ
02/05/22	Recipharm offers services to enable switch to next generation pMDI propellants	AQ
11/04/22	Recipharm completes US biologics acquisitions	AQ
11/03/22	Recipharm pledges support to conflict victims	AQ